Diet and nutraceutical interventions for headache management: A review of the evidence

Cephalalgia

Volumn 36, Issue 12, 2016, Pages 1112-1133

  Orr, Serena L ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Diet; headache; herbal medicines; migraine; nutraceuticals; vitamins

Indexed keywords

ALPHA TOCOPHEROL; ANTIMIGRAINE AGENT; BETA CAROTENE; DIPHENHYDRAMINE; DOCOSAHEXAENOIC ACID; GAMMA LINOLENIC ACID; GINKGOLIDE B; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN G ANTIBODY; LINOLENIC ACID; MAGNESIUM; MAGNESIUM ASPARTATE HYDROCHLORIDE TRIHYDRATE; MAGNESIUM CITRATE; MAGNESIUM OXIDE; MAGNESIUM PYRROLIDONE; MAGNESIUM SULFATE; NICOTINIC ACID; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PYROGLUTAMATE MAGNESIUM; RIBOFLAVIN; TANACETUM PARTHENIUM EXTRACT; TOCOPHEROL; TRI MAGNESIUM DICITRATE; UBIDECARENONE; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

AEROBIC EXERCISE; ATKINS DIET; BARIATRIC SURGERY; CLINICAL EFFECTIVENESS; CLUSTER HEADACHE; COGNITIVE BEHAVIORAL THERAPY; DIET THERAPY; FLUID INTAKE; GASTRIC BANDING; GASTRIC BYPASS SURGERY; HEADACHE; HISTAMINE FREE DIET; HUMAN; HYPERTENSION; KETOGENIC DIET; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW FAT DIET; LOW SUCROSE DIET; MIGRAINE; NONHUMAN; NUTRITIONAL COUNSELING; OBESITY; OLIGOANTIGENIC DIET; PETASITES; PETASITES HYBRIDUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM RESTRICTION; TANACETUM PARTHENIUM; TENSION HEADACHE; TRYPTOPHAN REDUCED DIET; VEGAN DIET; WEIGHT LOSS PROGRAM; ALTERNATIVE MEDICINE; DIETARY SUPPLEMENT; EVIDENCE BASED MEDICINE; PROCEDURES; TREATMENT OUTCOME;

COMPLEMENTARY THERAPIES; DIET THERAPY; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; EVIDENCE-BASED MEDICINE; HEADACHE; HUMANS; MIGRAINE DISORDERS; TREATMENT OUTCOME;

EID: 84992360105     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102415590239     Document Type: Review

References (130)

1. US National Library of Medicine. Complementary and Alternative Medicine, http://www.nlm.nih.gov/tsd/acquisitions/cdm/subjects24.html (2010, accessed 28 March 2015).
2. Nahin RL, Barnes P, Stussman B, et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009; 1-14.
3. Su D, Li L,. Trends in the use of complementary and alternative medicine in the United States: 2002-2007. J Health Care Poor Underserved 2011; 22: 296-301.
4. Barnes PM, Bloom B, Nahin R,. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; 12: 1-23.
5. Shmueli A, Shuval J,. Use of complementary and alternative medicine in Israel: 2000 vs. 1993. Isr Med Assoc J 2004; 6: 3-8.
6. Fischer FH, Lewith G, Witt CM, et al. High prevalence but limited evidence in complementary and alternative medicine: Guidelines for future research. BMC Complement Altern Med 2014; 14: 46-46.
7. Briggs J, Killen J,. Perspectives on complementary and alternative medicine research. JAMA 2013; 310: 6913692-6913692.
8. von Peter S, Ting W, Scrivani S, et al. Survey on the use of complementary and alternative medicine among patients with headache syndromes. Cephalalgia 2002; 22: 395-400.
9. Karakurum Göksel B, Coşkun O, Ucler S, et al. Use of complementary and alternative medicine by a sample of Turkish primary headache patients. Agri 2014; 26: 107-107.
10. Kristoffersen ES, Aaseth K, Grande RB, et al. Self-reported efficacy of complementary and alternative medicine: The Akershus study of chronic headache. J Headache Pain 2013; 14: 36-36.
11. Gaul C, Schmidt T, Czaja E, et al. Attitudes towards complementary and alternative medicine in chronic pain syndromes: A questionnaire-based comparison between primary headache and low back pain. BMC Complement Altern Med 2011; 11: 1-8.
12. Rossi P, Di Lorenzo G, Malpezzi MG, et al. Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia 2005; 25: 493-506.
13. Dalla Libera D, Colombo B, Pavan G, et al. Complementary and alternative medicine (CAM) use in an Italian cohort of pediatric headache patients: The tip of the iceberg. Neurol Sci 2014; 35 (Suppl 1): 145-148.
14. Bethell C, Kemper KJ, Gombojav N, et al. Complementary and conventional medicine use among youth with recurrent headaches. Pediatrics 2013; 132: e1173-e1183.
15. Chai NC, Scher AI, Moghekar A, et al. Obesity and headache: Part I-A systematic review of the epidemiology of obesity and headache. Headache 2014; 54: 219-234.
16. Winsvold BS, Sandven I, Hagen K, et al. Migraine, headache and development of metabolic syndrome: An 11-year follow-up in the Nord-Trøndelag Health Study (HUNT). Pain 2013; 154: 1305-1311.
17. Guldiken B, Guldiken S, Taskiran B, et al. Migraine in metabolic syndrome. Neurologist 2009; 15: 55-58.
18. Bigal ME, Liberman JN, Lipton RB,. Obesity and migraine: A population study. Neurology 2006; 66: 545-550.
19. Peterlin BL, Tietjen GE, Gower BA, et al. Ictal adiponectin levels in episodic migraineurs: A randomized pilot trial. Headache 2013; 53: 474-490.
20. Peterlin BL, Alexander G, Tabby D, et al. Oligomerization state-dependent elevations of adiponectin in chronic daily headache. Neurology 2008; 70: 1905-1911.
21. Dearborn JL, Schneider ALC, Gottesman RF, et al. Adiponectin and leptin levels in migraineurs in the Atherosclerosis Risk in Communities Study. Neurology 2014; 83: 2211-2218.
22. Chai N, Bond D, Moghekar A, et al. Obesity and headache: Part II-Potential mechanism and treatment considerations. Headache 2014; 54: 459-471.
23. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: Prospective cohort study. BMJ 2010; 340: c2701-c2701.
24. Newborg B,. Pseudotumor cerebri treated by rice-reduction diet. Arch Intern Med 1974; 133: 802-802.
25. Novack V, Fuchs L, Lantsberg L, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: A case series. Cephalalgia 2011; 31: 1336-1342.
26. Bond DS, Vithiananthan S, Nash JM, et al. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology 2011; 76: 1135-1138.
27. Hershey AD, Powers SW, Nelson TD, et al. Obesity in the pediatric headache population: A multicenter study. Headache 2009; 49: 170-177.
28. Di Lorenzo C, Coppola G, Sirianni G, et al. Migraine improvement during short lasting ketogenesis: A proof-of-concept study. Eur J Neurol 2015; 22: 170-177.
29. Verrotti A, Agostinelli S, Dinelli SD, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol 2013; 20: 394-397.
30. Bond DS, Leary KCO, Thomas JG, et al. Can weight loss improve migraine headaches in obese women? Rationale and design of the WHAM randomized controlled trial. Contemp Clin Trials 2014; 35: 133-144.
31. Scopp AL,. MSG and hydrolyzed vegetable protein induced headache: Review and case studies. Headache 1991; 31: 107-110.
32. Amer M, Woodward M, Appel LJ,. Effects of dietary sodium and the DASH diet on the occurrence of headaches: Results from randomised multicentre DASH-Sodium clinical trial. BMJ Open 2014; 4: 1-7.
33. Antonova M, Wienecke T, Olesen J, et al. Prostaglandins in migraine: Update. Curr Opin Neurol 2013; 26: 269-275.
34. Bic Z, Blix G, Hopp H, et al. The influence of a low-fat diet on incidence and severity of migraine headaches. J Womens Health Gend Based Med 1999; 8: 623-630.
35. Bunner AE, Agarwal U, Gonzales JF, et al. Nutrition intervention for migraine: A randomized crossover trial. J Headache Pain 2014; 15: 1-9.
36. Salfield S, Wardley B, Houlsby W, et al. Controlled study of exclusion of dietary vasoactive amines in migraine. Arch Dis Child 1987; 62: 458-460.
37. Egger J, Carter C, Wilson J, et al. Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. Lancet 1983; 15: 865-869.
38. Wantke F, Götz M, Jarisch R,. Histamine-free diet: Treatment of choice for histamine-induced food intolerance and supporting treatment for chronical headaches. Clin Exp Allergy 1993; 23: 982-985.
39. Arroyave Hernández C, Echavarría Pinto M, Hernández Montiel HL,. Food allergy mediated by IgG antibodies associated with migraine in adults. Rev Allerg Mex 2007; 54: 162-168.
40. Alpay K, Ertas M, Orhan EK, et al. Diet restriction in migraine, based on IgG against foods: A clinical double-blind, randomised, cross-over trial. Cephalalgia 2010; 30: 829-837.
41. Mitchell N, Hewitt CE, Jayakody S, et al. Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J 2011; 10: 85-85.
42. Maggioni F, Margoni M, Zanchin G,. Ketogenic diet in migraine treatment: A brief but ancient history. Cephalalgia 2011; 31: 1150-1151.
43. Sinha SR, Kossoff EH,. The ketogenic diet. Neurologist 2005; 11: 161-170.
44. de Almeida Rabello Oliveira M, da Rocha Ataíde T, de Oliveira SL, et al. Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci Lett 2008; 434: 66-70.
45. Schnabel T,. An experience with a ketogenic dietary in migraine. Ann Intern Med 1928; 2: 3412347-3412347.
46. Barborka CJ,. Migraine: Results of treatment by ketogenic diet in fifty cases. JAMA 1930; 95: 1825-1828.
47. Strahlman R,. Can ketosis help migraine sufferers? A case report. Headache 2006; 46: 182-182.
48. Di Lorenzo C, Curra A, Sirianni G, et al. Diet transiently improves migraine in two twin sistersse Possible role of ketogenesis? Funct Neurol 2013; 28: 305-308.
49. Urbizu A, Cuenca-León E, Raspall-Chaure M, et al. Paroxysmal exercise-induced dyskinesia, writer's cramp, migraine with aura and absence epilepsy in twin brothers with a novel SLC2A1 missense mutation. J Neurol Sci 2010; 295: 110-113.
50. Kossoff EH, Huffman J, Turner Z, et al. Use of the modified Atkins diet for adolescents with chronic daily headache. Cephalalgia 2010; 30: 1014-1016.
51. Farkas M, Mak E, Richter E, et al. EHMTI-0336. Metabolic diet therapy in the prophylactic treatment of migraine headache in adolescents by using ketogenic diet. J Headache Pain 2014; 15 (Suppl 1): 1-2.
52. Di Lorenzo C, Coppola G, Sirianni G, et al. Short term improvement of migraine headaches during ketogenic diet: A prospective observational study in a dietician clinical setting. J Headache Pain 2013; 14 (Suppl 1): P219-P219.
53. Dexter J, Roberts J, Byer J,. The five hour glucose tolerance test and effect of low sucrose diet in migraine. Headache 1978; 18: 91-94.
54. Unge G, Malmgren R, Olsson P, et al. Effects of dietary protein-tryptophan restriction upon 5-HT uptake by platelets and clinical symptoms in migraine-like headache. Cephalalgia 1983; 3: 213-218.
55. Spigt M, Weerkamp N, Troost J, et al. A randomized trial on the effects of regular water intake in patients with recurrent headaches. Fam Pract 2012; 29: 370-375.
56. Ramsden C, Faurot K, Zamora D, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: A randomized trial. Pain 2013; 154: 1-22.
57. Tassorelli C, Greco R, Morazzoni P, et al. Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: Studies in an animal model of migraine. Cephalalgia 2005; 25: 612-621.
58. Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting TRPA1 channel. Pain 2013; 154: 1-20.
59. Benemei S, Fusi C, Trevisan G, et al. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014; 171: 2552-2567.
60. Pittler M, Ernst E,. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004. CD002286.
61. Cady RK, Schreiber CP, Beach ME, et al. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Med Sci Monit 2005; 11: 65-70.
62. Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache 2011; 51: 1078-1086.
63. Maizels M, Blumenfeld A, Burchette R,. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache 2004; 44: 885-890.
64. Shrivastava R, Pechadre JC, John GW,. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: A prospective, open-label study. Clin Drug Investig 2006; 26: 287-296.
65. Ferro EC, Biagini AP, da Silva ÍE, et al. The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: Randomised study. Acupunct Med 2012; 30: 252-257.
66. Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention-a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25: 1031-1041.
67. Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1346-1353.
68. Fiebich B, Grozdeva M, Hess S, et al. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med 2005; 71: 12-19.
69. Wang G, Shum A, Lin Y, et al. Calcium channel blockade in vascular smooth muscle cells: Major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from Petasites formosanus. J Pharmacol Exp Ther 2001; 297: 240-246.
70. Orr SL, Venkateswaran S,. Nutraceuticals in the prophylaxis of pediatric migraine: Evidence-based review and recommendations. Cephalalgia 2014; 34: 568-583.
71. Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012; 39 (2 Suppl 2): 1-62.
72. Avula B, Wang YH, Wang M, et al. Simultaneous determination of sesquiterpenes and pyrrolizidine alkaloids from the rhizomes of Petasites hybridus (L.) G.M. et Sch. and dietary supplements using UPLC-UV and HPLC-TOF-MS methods. J Pharm Biomed Anal 2012; 70. 53:2;rm.
73. Danesch U, Rittinghausen R,. Safety of a patented special butterbur root extract for migraine prevention. Headache 2003; 43: 76-78.
74. Prieto JM,. Update on the efficacy and safety of Petadolex® a butterbur extract for migraine prophylaxis. Bot Targets Ther 2014; 4: 1-9.
75. Riboflavin,. Monograph. Altern Med Rev 2008; 13: 334-340.
76. Montagna P, Sacquegna T, Martinelli P, et al. Mitochondrial abnormalities in migraine. Preliminary findings. Headache 1988; 28: 477-480.
77. Lodi R, Lotti S, Cortelli P, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 2001; 54: 437-441.
78. Okada H, Araga S, Takeshima T, et al. Plasma lactic acid and pyruvic acid levels in migraine and tension-type headache. Headache 1998; 38: 39-42.
79. Lodi R, Kemp GJ, Montagna P, et al. Quantitative analysis of skeletal muscle bioenergetics and proton efflux in migraine and cluster headache. J Neurol Sci 1997; 146: 73-80.
80. 31P magnetic resonance spectroscopy interictal study. Pediatr Res 1997; 42: 866-871.
81. 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. Cephalalgia 2011; 31: 1243-1253.
82. Sangiorgi S, Mochi M, Riva R, et al. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 1994; 14: 21-23.
83. 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992; 42: 1209-1214.
84. Smith C,. The role of riboflavin in migraine. Can Med Assoc J 1946; 54: 589-591.
85. Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. Eur J Neurol 2004; 11: 4750477-4750477.
86. Schoenen J, Lenaerts M, Bastings E,. High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study. Cephalalgia 1994; 14: 328-329.
87. Di Lorenzo C, Pierelli F, Coppola G, et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 2009; 72: 158891594-158891594.
88. Sándor PS, Afra J, Ambrosini A, et al. Prophylactic treatment of migraine with beta-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000; 40: 30-35.
89. Schoenen J, Jacquy J, Lenaerts M,. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology 1998; 50: 466-470.
90. Nambiar N, Aiyappa C, Srinivasa R,. Oral riboflavin versus oral propranolol in migraine prophylaxis: An open label randomized controlled trial. Neurol Asia 2011; 16: 223-229.
91. Condò M, Posar A, Arbizzani A, et al. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009; 10: 361-365.
92. Markley HG,. Prophylactic treatment of headaches in adolescents with riboflavin. Cephalalgia 2009; 29 (Suppl 1): 100-100.
93. MacLennan SC, Wade FM, Forrest KML, et al. High-dose riboflavin for migraine prophylaxis in children: A double-blind, randomized, placebo-controlled trial. J Child Neurol 2008; 23: 1300-1304.
94. Bruijn J, Duivenvoorden H, Passchier J, et al. Medium-dose riboflavin as a prophylactic agent in children with migraine: A preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 2010; 30: 1426-1434.
95. Taylor FR,. Nutraceuticals and headache: The biological basis. Headache 2011; 51. 48411;hea.
96. Teigen L, Boes CJ,. An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia. 2015; 35: 912-922.
97. Martinez Cardenas V, Rodriguez M, Burke M, et al. Efficacy and safety of intravenous magnesium sulfate treatment in pediatric patients with headaches. Headache 2012; 52: 896-896.
98. Gertsch E, Loharuka S, Wolter-Warmerdam K, et al. Intravenous magnesium as acute treatment for headaches: A pediatric case series. J Emerg Med 2014; 46: 308-312.
99. Mauskop A, Altura BT, Cracco RQ, et al. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 1996; 36: 154-160.
100. Mauskop A, Altura BT, Cracco RQ, et al. Intravenous magnesium sulfate relieves cluster headaches in patients with low serum ionized magnesium levels. Headache 1995; 35: 597-600.
101. Orr SL, Aube A, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia 2015; 35: 271-284.
102. Choi H, Parmar N,. The use of intravenous magnesium sulphate for acute migraine: Meta-analysis of randomized controlled trials. Eur J Emerg Med 2014; 21: 2-9.
103. Shahrami A, Assarzadegan F, Hatamabadi HR, et al. Comparison of therapeutic effects of magnesium sulfate vs. dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med 2015; 48: 69-76.
104. Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache 1991; 31: 298-301.
105. Köseoglu E, Talaslioglu A, Gönül AS, et al. The effects of magnesium prophylaxis in migraine without aura. Magnes Res 2008; 21: 101-108.
106. Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, et al. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 2012; 150: 42048-42048.
107. Peikert A, Wilimzig C, Köhne-Volland R,. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-263.
108. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine-a double-blind, placebo-controlled study. Cephalalgia 1996; 16: 4369440-4369440.
109. Castelli S, Meossi C, Domenici R, et al. Magnesium in the prophylaxis of primary headache and other periodic disorders in children [article in Italian]. Pediatr Med Chir 1993; 15: 481-488.
110. Wang F, Van Den Eeden SK, Ackerson L, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: A randomized, double-blind, placebo-controlled trial. Headache 2003; 43: 601-610.
111. Gallelli L, Avenoso T, Falcone D, et al. Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium. Headache 2014; 54: 313-324.
112. Grazzi L, Andrasik F, Usai S, et al. Magnesium as a treatment for paediatric tension-type headache: A clinical replication series. Neurol Sci 2005; 25: 338-341.
113. Grazzi L, Andrasik F, Usai S, et al. Magnesium as a preventive treatment for paediatric episodic tension-type headache: Results at 1-year follow-up. Neurol Sci 2007; 28: 148-150.
114. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 1370141-1370141.
115. Sándor PS, DiClemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005; 64: 713-715.
116. Hershey AD, Powers SW, Vockell AL, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007; 47: 73-80.
117. Slater SK, Nelson TD, Kabbouche MA, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011; 31: 897-905.
118. Wagner W, Nootbaar-Wagner U,. Prophylactic treatment of migraine with gamma-linolenic and alpha-linolenic acids. Cephalalgia 1997; 17: 127-130.
119. Pradalier A, Bakouche P, Baudesson G, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: A double-blind study versus placebo. Cephalalgia 2001; 21: 818-822.
120. Harel Z, Gascon G, Riggs S, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health 2002; 31: 154-161.
121. Tajmirriahi M, Sohelipour M, Basiri K,. The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: A randomized single-blind clinical trial. Iran J Neurol 2012; 11: 21-24.
122. D'Andrea G, Bussone G, Allais G, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci 2009; 30 (Suppl 1): S121-S124.
123. Esposito M, Carotenuto M,. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: An open-label study. Neurol Sci 2011; 32: 79-81.
124. Esposito M, Ruberto M, Pascotto A, et al. Nutraceutical preparations in childhood migraine prophylaxis: Effects on headache outcomes including disability and behaviour. Neurol Sci 2012; 33: 1365-1368.
125. Usai S, Grazzi L, Andrasik F, et al. An innovative approach for migraine prevention in young age: A preliminary study. Neurol Sci 2010; 31 (Suppl 1): S181-S183.
126. Markley HG,. Topical agents in the treatment of cluster headache. Curr Pain Headache Rep 2003; 7: 1390143-1390143.
127. Levin M,. Herbal treatment of headache. Headache 2012; 52 (Suppl 2): 76-80.
128. Snyder FJ, Dundas ML, Kirkpatrick C, et al. Use and safety perceptions regarding herbal supplements: A study of older persons in southeast Idaho. J Nurt Elder 2009; 28: 81-95.
129. Allais G, Castagnoli Gabellari I, Burzio C, et al. Premenstrual syndrome and migraine. Neurol Sci 2012; 33 (Suppl 1): S111-S115.
130. Kooreman P, Baars EW,. Patients whose GP knows complementary medicine tend to have lower costs and live longer. Eur J Heal Econ 2012; 13: 769-776.